Ex vivo models of HIV sexual transmission and microbicide development

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 73-78

  Ariën, Kevin K ^a   Kyongo, Jordan K ^a   Vanham, Guido ^a,b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cervix; HIV; In vitro; Microbicides; Modeling; Transmission; Vagina

Indexed keywords

MICROBICIDE;

ARTICLE; CELL LINE; EPITHELIUM CELL; EX VIVO STUDY; FEMALE GENITAL SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHYSICAL CHEMISTRY; PRODUCT DEVELOPMENT; SAFETY; SEXUAL TRANSMISSION; VAGINA; VIRUS REPLICATION;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-RETROVIRAL AGENTS; CELLS, CULTURED; DRUG DESIGN; EPITHELIAL CELLS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL;

EID: 84857134390     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304661     Document Type: Article

References (78)

1. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 2011; 8: 94-103.
2. García-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral preexposure prophylaxis for HIV prevention. Trends PharmacolSci 2010; 31: 74-81.
3. Rey D. Post-exposure prophylaxis for HIV infection. Expert Rev Anti Infect Ther 2011; 9: 431-442.
4. Barber TJ, Benn PD. Postexposure prophylaxis for HIV following sexual exposure. CurrOpin HIV AIDS 2010; 5: 322-326.
5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
6. AbdoolKarim Q, AbdoolKarim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviralmicrobicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIVprevention in men who have sex with men. N Engl J Med 2010; 363: 2587-2599.
8. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL- 1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in femalesex workers: a randomised controlled trial. Lancet 2002; 360: 971-977.
9. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 504-510.
10. Thompson KA, Malamud D, Storey BT. Assessment of the antimicrobial agent C31G as a spermicide: comparison with nonoxynol-9. Contraception 1996; 53: 313-318.
11. Bax R, Douville K, McCormick D, et al. Microbicides: evaluating multiple formulations of C31G. Contraception 2002; 66: 365-368.
12. Ballagh SA, Baker JM, Henry DM, Archer DF. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002; 66: 369-375.
13. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al. Safety and acceptability of the candidate microbicideCarraguard in ThaiWomen: findings from a Phase II Clinical Trial. J Acquir Immune Defic Syndr 2006; 43: 327-334.
14. Pistorius AG, van de Wijgert JH, Sebola M, et al. Microbicide trials for preventing HIV/AIDS in South Africa: phase II trial partricipants' experiences and psychological needs. SAHARA J 2004; 1: 78-86.
15. Ariën KK, Jespers V, Vanham G. HIV sexual transmission and microbicides. Rev Med Virol 2011; 21: 110-133.
16. Pirrone V, Wigdahl B, Krebs FC. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. AntiviralRes 2011; 90: 168-182.
17. Selhorst P, Vazquez AC, Terrazas-Aranda K, et al. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother 2011; 55: 1403-1413.
18. van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis 2010; 23: 621-627.
19. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI based vaginal microbicide strategies? Antiviral Res 2006; 71: 343-350.
20. Yu T, Malcolm K, Woolfson D, Jones DS, Andrews GP. Vaginal geldrug delivery systems: understanding rheological characteristics and performance. Expert Opin Drug Deliv 2011 Jul 5 [Epub ahead of print]
21. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicidevaginal rings. Antiviral Res 2010; 88 Suppl 1: S30-S39.
22. Turpin JA. Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges. Drug Deliv Transl Res 2011; 1: 194-200.
23. Doncel G, Mauck C. Vaginal microbicides: a novel approach to preventing sexual transmission of HIV. Curr HIV/AIDS Rep 2004; 1: 25-32.
24. Lackman-Smith C, Osterling C, Luckenbaugh K, et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008; 52: 1768-1781.
25. Heyndrickx L, Vermoesen T, Vereecken K, et al. Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. J Virol Methods 2008; 148: 166-173.
26. Terrazas-Aranda K, Van Herrewege Y, Lewi PJ, Van Roey J, Vanham G. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir Chem Chemother 2007; 18: 141-151.
27. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438: 99-102.
28. Shen R, Richter HE, Smith PD. Early HIV-1 targetcells in human vaginal and ectocervicalmucosa. Am J Reprod Immunol 2011; 65: 261-267.
29. Kawamura T, Kurtz SE, Blauvelt A, Shimada S. The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci 2005; 40: 147-155.
30. Bull M, Learn G, Genowati I, et al. Compartmentalization of HIV- 1 within the female genitaltract is due to monotypic and lowdiversity variants not distinct viral populations. PLoS One 2009; 4: e7122.
31. Prada N, Davis B, Jean-Pierre P, et al. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr 2008; 49: 117-122.
32. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-1508.
33. Fichorova RN, Rheinwald JG, Anderson DJ. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 1997; 57: 847-855.
34. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010; 5: e9310.
35. Asin SN, Fanger MW, Wildt-Perinic D, et al. Transmission of HIV-1 by primary human uterine epithelial cells and stromalfibroblasts. J Infect Dis 2004; 190: 236-245.
36. Bouschbacher M, Bomsel M, Verronèse E, et al. Early events in HIV transmission through a human reconstructed vaginal mucosa. AIDS 2008; 22: 1257-1266.
37. Fahey JV, Prabhala RH, Guyre PM, Wira CR. Antigen-presenting cells in the human female reproductive tract: analysis of antigen presentation in pre- and post-menopausal women. Am J Reprod Immunol 1999; 42: 49-57.
38. Fahey JV, Humphrey SL, Stern JE, Wira CR. Secretory component production by polarized epithelial cells from the human femalereproductive tract. Immunol Invest 1998; 27: 167-180.
39. Bobardt MD, Chatterji U, Selvarajah S, et al. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 2007; 81: 395-405.
40. Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 2000; 6: 475-479.
41. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6: e1000852.
42. Gali Y, Ariën KK, Praet M, et al. Development of an in vitro dualchamber model of the female genital tract as a screening tool for epithelial toxicity. J Virol Methods 2010; 165: 186-197.
43. Ariën KK, Vanham G, Gali Y. A Dual-ChamberModel of the Female Genital Tract to Evaluate Epithelial Toxicity of Candidate Anti-HIV Microbicides. Curr Protoc Cell Biol 2011; Chapter 26: Unit 26.13
44. Mesquita PM, Cheshenko N, Wilson SS, et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model ofmicrobicide safety. J Infect Dis 2009; 200: 599-608.
45. Van Herrewege Y, Michiels J, Waeytens A, et al. A dualchambermodel of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIVmicrobicides. Antiviral Res 2007; 74: 111-124.
46. Ayehunie S, Cannon C, Larosa K, et al. Development of an in vitro alternative assay method for vaginal irritation. Toxicology 2011; 279: 130-138.
47. Gali Y, Delezay O, Brouwers J, et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother 2010; 54: 5105-5114.
48. Hillier SL, Moench T, Shattock R, et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39: 1-8.
49. Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65: 325-333.
50. Sabatté J, Lenicov FR, Cabrini M, et al. The role of semen in sexual transmission of HIV: beyond a carrier for virus particles. Microbes Infect 2011; 13: 977-982.
51. Doncel GF, Joseph T, Thurman AR. Role of semen in HIV-1 transmission: inhibitor or facilitator? Am J Reprod Immunol 2011; 65: 292-301.
52. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011; 6: e16475.
53. Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005; 26: 459-469.
54. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59: 91-95.
55. Neurath AR, Strick N, Li YY. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect Dis 2006; 6: 150.
56. Cohen CR, Duerr A, Pruithithada N, et al. Bacterial vaginosis and HIVseroprevalence among female commercial sex workers in Chiang Mai, Thailand. AIDS 1995; 9: 1093-1097.
57. Hashemi FB, Ghassemi M, Roebuck KA, Spear GT. Activation of human immunodeficiency virus type 1 expression by Gardnerellavaginalis. J Infect Dis 1999; 179: 924-930.
58. Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT. Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis. J Infect Dis 2000; 181: 1574-1580.
59. Garg S, Kandarapu R, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 2003; 17: 17-32.
60. Garg S, Goldman D, Krumme M, et al. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 2010; 88 Suppl 1: S19-S29.
61. Doncel GF, Clark MR. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res 2010; 88 Suppl 1: S10-S18.
62. Abner SR, Guenthner PC, Guarner J, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 2005; 192: 1545-1556.
63. Fletcher P, Kiselyeva Y, Wallace G, et al. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits humanimmunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005; 79: 11179-11186.
64. Fletcher PS, Elliott J, Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20: 1237-1245.
65. Cummins JE Jr, Guarner J, Flowers L, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007; 51: 1770-1779.
66. Southern PJ, Horbul JE, Miller BR, Maher DM. Coming of age: reconstruction of heterosexual HIV-1 transmission in human ex vivo organ culture systems. Mucosal Immunol 2011; 4: 383-396.
67. Ariën KK, Gali Y, Vanham G. The gatekeeper hypothesis challenged in a human cervico-vaginal tissue model for HIV-1 transmission. Mucosal Immunol 2011; 4: 121-122.
68. Dezzutti CS, Guenthner PC, Cummins JE Jr, et al. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis 2001; 183: 1204-1213.
69. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74: 5577-5586.
70. Anderson DJ, Pudney J, Schust DJ. Caveats associated with the use of human cervical tissue for HIV and microbicide research. AIDS 2010; 24: 1-4.
71. Merbah M, Introini A, Fitzgerald W, et al. Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol 2011; 65: 268-278.
72. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS 2011; 25: 1971-1979.
73. Fischetti L, Barry SM, Hope TJ, Shattock RJ. HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS 2009; 23: 319-328.
74. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2: e298.
75. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet 2007; 369: 643-656.
76. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-666.
77. Ganor Y, Bomsel M. HIV-1 transmission in the male genital tract. Am J Reprod Immunol 2011; 65: 284-291.
78. Ganor Y, Zhou Z, Tudor D, et al. Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol 2010; 3: 506-522.